HOME > TOP STORIES
TOP STORIES
-
REGULATORY MHLW to Ask All Generic Makers in Japan to Execute Self-Inspections
March 4, 2024
-
BUSINESS Moderna Japan Taps Kazumasa Nagayama as New President
March 4, 2024
-
REGULATORY Generic Mergers, Product Consolidations Unlikely to Pose Antitrust Issue: FTC Official
March 1, 2024
-
REGULATORY MHLW Sets Out to Beef Up Inspector Skills with Nationwide Sharing of GMP Reports
February 29, 2024
-
BUSINESS Insmed Revs Up for Product Expansion in Japan, Arikayce Frontline Filing Set for 2026 with More to Follow
February 28, 2024
-
BUSINESS Japan Drug Market Tops 11 Trillion Yen for 1st Time Driven by Oncologics: IQVIA
February 27, 2024
-
BUSINESS As Wegovy Hits Japan Market, Novo Re-Stresses Need for Proper Use
February 26, 2024
-
REGULATORY Drug Comparisons in Promotional Activities Allowed under 4 Conditions: MHLW
February 26, 2024
-
REGULATORY Japan to Revisit Vaccine Lot Release Process to Eradicate Double Testing
February 22, 2024
-
REGULATORY New Doctor Payment Disclosure Rule to Apply to Foreign Firms with Japan Subsidiaries
February 21, 2024
-
REGULATORY Japan to End Public Aid for COVID Drugs at March-End
February 21, 2024
-
REGULATORY Xocova, Astellas’s Gastric Cancer Med Up for PAFSC Review on March 4; Pfizer’s Bispecific, RSV Jab Also on Agenda
February 20, 2024
-
BUSINESS Gilead Japan Ramping Up Sales Force with Trodelvy Now under Review
February 20, 2024
-
BUSINESS Active Pharma Hid Botched API Production, Source Reveals Details of Violations
February 19, 2024
-
BUSINESS Cancer Specialist BeiGene Set to Enter Japan Market as Early as This Year
February 16, 2024
-
BUSINESS GSK Japan Nets 11% Sales Rise in 2023, Sees 6% CAGR through 2026: President
February 15, 2024
-
REGULATORY Japan to Announce New Drug Prices on March 5
February 15, 2024
-
REGULATORY Chuikyo Issues 2024 Reform Recommendation; 1,000 Yen Premium Set for Inpatient Biosimilar Use
February 14, 2024
-
REGULATORY Japan Approves Jardiance for CKD, Label Expansion for Opdivo and More
February 13, 2024
-
BUSINESS Medac Poised to Cement Japan Foothold in RA, Eyes Rare Disease Launch Too: CEO
February 9, 2024
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
